Q-Line Biotech IPO
Q-Line Biotech IPO is a book built issue of ₹44,72,000 crores. The issue is entirely a fresh issue. The subscription opens on 21 May '26 and closes on 25 May '26, with the basis of allotment expected to be finalised on 26 May '26. The shares are scheduled to list on NSE. The price band is set at ₹326 to ₹343 per share with a minimum lot size of 400 shares. Hem Securities Ltd and Share India Capital Services Pvt Ltd are the book-running lead managers, while Purva Sharegistry (India) Pvt.Ltd. is the registrar of the issue; for detailed information, refer directly to the official Q-Line Biotech IPO RHP.
Free Demat with Zero AMC*
Q-Line Biotech IPO Subscription Breakdown
| Investory Category | Subscription Percentage | Amount Raised (₹ Crores) |
|---|---|---|
| Qualified Institutional Buyers (QIBs) | 50% | 22,36,000 crores |
| Non-Institutional Investors (NIIs) | 15% | 6,70,800 crores |
| Retail Individual Investors (RIIs) | 35% | 15,65,200 crores |
About Q-Line Biotech Ltd IPO
Q-Line Biotech Ltd., incorporated in 2010, operates in the diagnostics and healthcare segment, focusing on the development, manufacturing, and distribution of reagents, diagnostic kits, and medical equipment. The company caters to hospitals, diagnostic labs, and medical institutions across India, either directly or through its distribution network.
Its product portfolio spans multiple diagnostic segments, including clinical chemistry, haematology, immunodiagnostics, molecular diagnostics, and rapid/POC testing solutions. In addition to reagents and consumables, the company also deals in in-vitro diagnostic (IVD) equipment and pathology devices.
Q-Line has built in-house manufacturing capabilities with a strong focus on R&D, reverse engineering, and quality control. As of December 2025, it had an annual capacity of around 1.4 million diagnostic kits and 1,200 Selectra machines. Its operations are supported by a mix of in-house teams and third-party workforce to ensure scale and efficiency.
Q-Line Biotech IPO Strengths & Weaknesses
Strong manufacturing and R&D capabilities with a focus on quality.
Diversified product portfolio across multiple diagnostic segments.
Pan-India distribution network with wide market reach.
Long-standing relationships with hospitals and diagnostic players.
Experienced promoters and management team.
Q-Line Biotech IPO Issue Details
| Issue Composition: | |
|---|---|
| Face Value | ₹10 per share |
| Total Issue Size | 44,72,000 shares (aggregating up to ₹2,74,400 crores) |
| Fresh Issue | 5,94,000 shares (aggregating up to ₹59,40,000 crores) |
| Offer for Sale | 0 shares of ₹10 (aggregating up to To be announced) |
| Issue Type | Book building |
| Post-Issue Shareholding Pattern: | |
|---|---|
| Pre-Issue Shareholding | 96.77 shares |
| Post-Issue Shareholding | 0 shares |
Q-Line Biotech IPO Shares
| Minimum Shares | Maximum Shares |
|---|---|
| -- | -- |
The lot size of Q-Line Biotech ipo has been designed to ensure broad participation while maintaining optimal price discovery.
How to Apply for Q-Line Biotech IPO
- Log in to your Choice account
- Select IPO
- Enter the number of lots and your price
- Verify UPI ID
- Complete the transaction on your UPI app
Q-Line Biotech IPO Contact & Registrar Details
Contact Details
Address
298-281 Transport Nagar Kanpur Road Adjacent Transport Nagar Lucknow
Phone Number
Website
Registrar Details
Registrar Name
Purva Sharegistry (India) Pvt.Ltd.
Phone Number
Q-Line Biotech Lead Manager(s)
| Book Running Lead Manager(s) |
|---|
| Hem Securities Ltd | Share India Capital Services Pvt Ltd |
